Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zolbetuximab, Durvalumab, and FLOT in CLDN18.2-Positive Gastric/GEJ Cancer
NCT07872722Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2026
- Primary completion
- Mar 2030
- Countries
- 1
01
Overview
A Phase 2 trial of zolbetuximab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Aug 2026; status: recruiting.
02
Drugs
zolbetuximab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07872722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07872722.